Searched for
COVID ANTIVIRAL MOLNUPIRAVIR
New study finds link between Covid antiviral drug & virus mutationsA study published in the journal Nature has found a link between the COVID-19 antiviral drug molnupiravir and a pattern of mutations in the...- Companies stare at huge losses as unsold Covid drugs pile upDuring the past two years, there were sky-rocketing sales of Covid-19 portfolio of drugs, sometimes even severe shortages. But now the indu...
- Molnupiravir reduced Covid-linked hospitalisation by over 65%: StudyThe Phase III trial results of Hetero's Movfor (Molnupiravir), presented at the Conference on Retroviruses and Opportunistic Infections (CR...
- Phase III trials of COVID drug Movfor show positive results, says HeteroThe results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12...
- Do Molnupiravir's benefits outweigh risks? Here's what experts sayThe ICMR Director-General Balram Bhargava had said that molnupiravir has major safety concerns and has not been included in the national pr...
- India to become hub for Covid-19 antiviral generic drugs: FitchGeneric molnupiravir will increase access in India and other low- and middle-income countries (LMICs), while simplifying current supply cha...
- Lupin launches Molnulup for COVID-19 treatmentMolnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 pati...
- Merck says no safety concerns observed in molnupiravir phase-3 trial, shared relevant data with DCGIMerck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical ...
- Covid cases on the rise, experts call for newer drugs, faster approvalsThe Drug Controller General of India had last week approved Merck and Ridgeback’s antiviral molnupiravir for the treatment of mild-to-moder...
- Dr Reddy's Laboratories to introduce Molnupiravir to treat COVID-19 shortlyThe drug firm said it is able to manufacture the active pharmaceutical ingredient (API) as well as the formulation for Molnupiravir, and ha...
- Cipla to launch Molnupiravir under Cipmolnu brand name for COVID-19 treatment"This launch is yet another step in our endeavour to enable access to all treatments in COVID care. We continue to be guided by the power o...
- Torrent Pharma to launch Molnupiravir under Molnutor brand name to treat COVID-19Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback's molnupiravir under the brand name Molnutor in India for the trea...
- USFDA approves COVID antiviral pill molnupiravir for emergency useThe USFDA also said the drug should be given for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or cl...
- Merck v Pfizer: here's how the two new COVID antiviral drugs work and will be usedUK approved molnupiravir, the COVID antiviral developed by Merck and Ridgeback Therapeutics. Now, Pfizer has released results from trials o...
- COVID antiviral drug Molnupiravir efficacy against hospitalization or death drops to 30% compared to placebo groupThe analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...
- Sun Pharma says gearing up to launch COVID drug molnupiravirThe company said the Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COV...
- MSD enters pact with UN-backed MPP to license COVID drug molnupiravir in 105 countries including IndiaUnder the terms of the agreement, MPP will be permitted to further license non-exclusive sub-licences to manufacturers and diversify the ma...
- India's Everest Organics starts making ingredient for Merck's COVID-19 pillThe Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...
- Aurobindo Pharma, MSN Labs seek DGCI nod for Phase-III trials of Merck's molnupiravirIn a meeting held on October 4, both the companies said that they “they want to discontinue phase III trial in moderate Covid-19 patients a...
- A new oral antiviral drug for COVID-19 is being tested in humans - can it make a difference?One promising drug that could improve things is molnupiravir, an antiviral that's moving into the final stages of testing in humans. Resear...
Load More
